Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases

P. R.S. Lagacé-Wiens; F. Tailor; P. Simner; M. DeCorby; J. A. Karlowsky; A. Walkty; D. J. Hoban; G. G. Zhanel

doi:10.1128/AAC.01722-10

Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases

P. R.S. Lagacé-Wiens, F. Tailor, P. Simner, M. DeCorby, J. A. Karlowsky, A. Walkty, D. J. Hoban, G. G. Zhanel

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Abstract

The novel non-β-lactam β-lactamase inhibitor NXL104, in combination with cefepime, ceftazidime, ceftriaxone, amdinocillin, and meropenem, was tested against 190 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, 94 AmpC-hyperproducing E. coli isolates, and 8 AmpC/ESBL-coexpressing E. coli isolates. NXL104 restored 100% susceptibility to the partner cephalosporins for all isolates tested. Amdinocillin and meropenem MICs were modestly improved (2 to 32 times lower) by NXL104. These results suggest that NXL104 may be useful in combination with β-lactams for the treatment of infections caused by ESBL- and AmpC-producing Enterobacteriaceae.

Original language	English (US)
Pages (from-to)	2434-2437
Number of pages	4
Journal	Antimicrobial agents and chemotherapy
Volume	55
Issue number	5
DOIs	https://doi.org/10.1128/AAC.01722-10
State	Published - May 2011
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.01722-10

Fingerprint

Dive into the research topics of 'Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases'. Together they form a unique fingerprint.

Cite this

Lagacé-Wiens, P. R. S., Tailor, F., Simner, P., DeCorby, M., Karlowsky, J. A., Walkty, A., Hoban, D. J., & Zhanel, G. G. (2011). Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrobial agents and chemotherapy, 55(5), 2434-2437. https://doi.org/10.1128/AAC.01722-10

Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. / Lagacé-Wiens, P. R.S.; Tailor, F.; Simner, P. et al.
In: Antimicrobial agents and chemotherapy, Vol. 55, No. 5, 05.2011, p. 2434-2437.

Research output: Contribution to journal › Article › peer-review

Lagacé-Wiens, PRS, Tailor, F, Simner, P, DeCorby, M, Karlowsky, JA, Walkty, A, Hoban, DJ & Zhanel, GG 2011, 'Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases', Antimicrobial agents and chemotherapy, vol. 55, no. 5, pp. 2434-2437. https://doi.org/10.1128/AAC.01722-10

Lagacé-Wiens PRS, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A et al. Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrobial agents and chemotherapy. 2011 May;55(5):2434-2437. doi: 10.1128/AAC.01722-10

@article{aaec52370054412bb9b849e67b7c0b88,

title = "Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases",

abstract = "The novel non-β-lactam β-lactamase inhibitor NXL104, in combination with cefepime, ceftazidime, ceftriaxone, amdinocillin, and meropenem, was tested against 190 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, 94 AmpC-hyperproducing E. coli isolates, and 8 AmpC/ESBL-coexpressing E. coli isolates. NXL104 restored 100% susceptibility to the partner cephalosporins for all isolates tested. Amdinocillin and meropenem MICs were modestly improved (2 to 32 times lower) by NXL104. These results suggest that NXL104 may be useful in combination with β-lactams for the treatment of infections caused by ESBL- and AmpC-producing Enterobacteriaceae.",

author = "Lagac{\'e}-Wiens, {P. R.S.} and F. Tailor and P. Simner and M. DeCorby and Karlowsky, {J. A.} and A. Walkty and Hoban, {D. J.} and Zhanel, {G. G.}",

year = "2011",

month = may,

doi = "10.1128/AAC.01722-10",

language = "English (US)",

volume = "55",

pages = "2434--2437",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases

AU - Lagacé-Wiens, P. R.S.

AU - Tailor, F.

AU - Simner, P.

AU - DeCorby, M.

AU - Karlowsky, J. A.

AU - Walkty, A.

AU - Hoban, D. J.

AU - Zhanel, G. G.

PY - 2011/5

Y1 - 2011/5

N2 - The novel non-β-lactam β-lactamase inhibitor NXL104, in combination with cefepime, ceftazidime, ceftriaxone, amdinocillin, and meropenem, was tested against 190 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, 94 AmpC-hyperproducing E. coli isolates, and 8 AmpC/ESBL-coexpressing E. coli isolates. NXL104 restored 100% susceptibility to the partner cephalosporins for all isolates tested. Amdinocillin and meropenem MICs were modestly improved (2 to 32 times lower) by NXL104. These results suggest that NXL104 may be useful in combination with β-lactams for the treatment of infections caused by ESBL- and AmpC-producing Enterobacteriaceae.

AB - The novel non-β-lactam β-lactamase inhibitor NXL104, in combination with cefepime, ceftazidime, ceftriaxone, amdinocillin, and meropenem, was tested against 190 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, 94 AmpC-hyperproducing E. coli isolates, and 8 AmpC/ESBL-coexpressing E. coli isolates. NXL104 restored 100% susceptibility to the partner cephalosporins for all isolates tested. Amdinocillin and meropenem MICs were modestly improved (2 to 32 times lower) by NXL104. These results suggest that NXL104 may be useful in combination with β-lactams for the treatment of infections caused by ESBL- and AmpC-producing Enterobacteriaceae.

UR - http://www.scopus.com/inward/record.url?scp=79955537450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955537450&partnerID=8YFLogxK

U2 - 10.1128/AAC.01722-10

DO - 10.1128/AAC.01722-10

M3 - Article

C2 - 21357295

AN - SCOPUS:79955537450

SN - 0066-4804

VL - 55

SP - 2434

EP - 2437

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 5

ER -

Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this